Standard Biotools (LAB) Asset Writedowns and Impairment (2019 - 2022)
Standard Biotools (LAB) reported Asset Writedowns and Impairment of $3.5 million for Q2 2022, up 775.0% quarter-over-quarter from $400000.0 in Q4 2019.
Standard Biotools (LAB) Asset Writedowns and Impairment (2019 - 2022) Analysis & Trends
Standard Biotools (LAB) has 2 years of Asset Writedowns and Impairment data on file, last reported at $3.5 million in Q2 2022.
- Asset Writedowns and Impairment for Q2 2022 came in at $3.5 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $3.5 million (changed 0.0% YoY), and the FY2022 annual result was $3.5 million, changed N/A from the prior year.
- Asset Writedowns and Impairment advanced to $3.5 million in Q2 2022 per LAB's latest filing, from $400000.0 in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $3.5 million in Q2 2022 and troughed at $400000.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn |
| 10 | Standard Biotools | 344.96 Mn | -110.22 Mn | 11.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 3.50 Mn |
| Jun 30, 2022 | 3.50 Mn |
| Dec 31, 2019 | 400,000.00 |
| Dec 31, 2019 | 400,000.00 |